CAR-engineered lymphocyte persistence is governed by a FAS ligand-FAS autoregulatory circuit.
Saved in:
| Title: | CAR-engineered lymphocyte persistence is governed by a FAS ligand-FAS autoregulatory circuit. |
|---|---|
| Authors: | Yi F; Immuno-Oncology Program, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA., Cohen T; Immuno-Oncology Program, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA.; Department of Pediatric Hematology/Oncology, Weill Cornell Medical College, New York, NY, USA., Zimmerman N; Immuno-Oncology Program, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA., Dündar F; Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA.; Applied Bioinformatics Core, Weill Cornell Medicine, New York, NY, USA.; Catenion, Berlin, Germany., Zumbo P; Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA.; Applied Bioinformatics Core, Weill Cornell Medicine, New York, NY, USA., Eltilib R; Immuno-Oncology Program, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA., Brophy EJ; Immuno-Oncology Program, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA., Arkin H; Immuno-Oncology Program, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA., Feucht J; Center for Cell Engineering, MSKCC, New York, NY, USA.; Cluster of Excellence iFIT, University Children's Hospital Tübingen, Tübingen, Germany., Gormally MV; Immuno-Oncology Program, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA.; Cell Therapy Service, Department of Medicine, MSKCC, New York, NY, USA., Hackett CS; Department of Medicine, Weill Cornell Medicine, New York, NY, USA., Kropp KN; Immuno-Oncology Program, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA., Etxeberria I; Immuno-Oncology Program, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA., Chandran SS; Immuno-Oncology Program, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA., Zhao Z; Center for Cell Engineering, MSKCC, New York, NY, USA.; Columbia Initiative in Cell Engineering and Therapy, Columbia University, New York, NY, USA., Cai W; Molecular Pharmacology Program, MSKCC, New York, NY, USA., Daniyan AF; Cell Therapy Service, Department of Medicine, MSKCC, New York, NY, USA.; Department of Medicine, Weill Cornell Medicine, New York, NY, USA.; Leukemia Service, Department of Medicine, MSKCC, New York, NY, USA., Park JH; Center for Cell Engineering, MSKCC, New York, NY, USA.; Cell Therapy Service, Department of Medicine, MSKCC, New York, NY, USA.; Department of Medicine, Weill Cornell Medicine, New York, NY, USA.; Leukemia Service, Department of Medicine, MSKCC, New York, NY, USA., Lareau CA; Computational and Systems Biology Program, MSKCC, New York, NY, USA., Hsu KC; Immuno-Oncology Program, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA.; Center for Cell Engineering, MSKCC, New York, NY, USA.; Department of Medicine, Weill Cornell Medicine, New York, NY, USA.; Adult Bone Marrow Transplantation Service, MSKCC, New York, NY, USA.; Immunology Program, Sloan Kettering Institute, MSKCC, New York, NY, USA., Sadelain M; Center for Cell Engineering, MSKCC, New York, NY, USA.; Columbia Initiative in Cell Engineering and Therapy, Columbia University, New York, NY, USA., Betel D; Applied Bioinformatics Core, Weill Cornell Medicine, New York, NY, USA.; Department of Medicine, Weill Cornell Medicine, New York, NY, USA.; Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, USA., Klebanoff CA; Immuno-Oncology Program, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA. klebanoc@mskcc.org.; Center for Cell Engineering, MSKCC, New York, NY, USA. klebanoc@mskcc.org.; Cell Therapy Service, Department of Medicine, MSKCC, New York, NY, USA. klebanoc@mskcc.org.; Department of Medicine, Weill Cornell Medicine, New York, NY, USA. klebanoc@mskcc.org.; Parker Institute for Cancer Immunotherapy, New York, NY, USA. klebanoc@mskcc.org. |
| Source: | Nature cancer [Nat Cancer] 2025 Oct; Vol. 6 (10), pp. 1638-1655. Date of Electronic Publication: 2025 Jul 22. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101761119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2662-1347 (Electronic) Linking ISSN: 26621347 NLM ISO Abbreviation: Nat Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
